Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area
Authors:
- J HamiltonJHJ Hamilton
- I B McInnesIMI B McInnes
- E A ThomsonETE A Thomson
- D PorterDPD Porter
- J A HunterJHJ A Hunter
Open Access
- 1 June 2001
- journal article
- clinical trial
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 60 (6) , 566-572
Abstract
OBJECTIVE To compare the risk-benefit ratio of intramuscular gold (gold sodium thiomalate (GST)) and methotrexate (MTX) in a population with rheumatoid arthritis (RA) from a deprived area. METHODS Patients with active RA were randomly assigned to open treatment with GST or MTX. Clinical and laboratory assessment was performed at 0, 12, 24, and 48 weeks. Results were analysed on an intention to treat basis. RESULTS 141 patients were recruited—72 were randomly allocated to GST and 69 to MTX. There were no statistically significant differences found in either the clinical or demographic variables at baseline. At 48 weeks 31 (43%) patients continued to receive GST and 43 (62%) MTX. The median MTX dose achieved was 10 mg. Gold caused significantly more withdrawals for toxicity (43% GST v 19% MTX, p=0.0026, log rank test). Both groups experienced a significant improvement in erythrocyte sedimentation rate, C reactive protein, Ritchie Articular Index, and pain score by 24 weeks (pCONCLUSION GST and low dose MTX showed equivalent efficacy, but toxicity was more common in patients treated with GST. GST, although more toxic, remains a useful alternative for patients in whom MTX is contraindicated.Keywords
This publication has 38 references indexed in Scilit:
- Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 1999
- Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 1997
- Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal studyRheumatology, 1997
- A Risk-Benefit Assessment of Slow-Acting Antirheumatic Drugs in Rheumatoid ArthritisDrug Safety, 1994
- Low‐dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. results of a multicenter randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 1993
- Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?Annals of the Rheumatic Diseases, 1993
- Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis.Thorax, 1991
- Association between gold induced skin rash and remission in patients with rheumatoid arthritis.Annals of the Rheumatic Diseases, 1989
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- STANFORD HEALTH ASSESSMENT QUESTIONNAIRE MODIFIED TO ASSESS DISABILITY IN BRITISH PATIENTS WITH RHEUMATOID ARTHRITISRheumatology, 1986